Company intelligence / Profile preview
EvviVax
Rome, Italyevvivax.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
EvviVax has demonstrated preclinical efficacy of DNA cancer vaccines (e.g., Tel-eVax) in animal models with tumor reduction and successful immune response; its COVID-19 veterinary vaccine showed neutralizing antibodies in preclinical/early clinical trials for pets.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- DNA vaccineVaccineViral vectorLipid nanoparticle delivery therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
TakisApplied DNA Sciences/LineaRx
Beyond the preview
Go deeper on EvviVax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EvviVax.